Signal Explorer

Clinical Trial Result Secondary Endpoint Mentioned Combination Therapy Mentioned Lead Asset Progress

Patient Retention High Interim Data Positive Fda Aligned Publication Positive

Fast Track Granted Orphan Status Granted Fast Track Designation Received Breakthrough Therapy Granted Board Committee Member Listing Fda Breakthrough Device Designation Ce Mark Received Fda Aligned Rmat Designation Received Publication Positive

Regulatory Designation Only Clinical Trial Result Combination Therapy Mentioned

Orphan Drug Designation

Secondary Endpoint Mentioned Clinical Trial Result Lead Asset Progress Indication Expansion Clinical Hold

Interim Data Positive Board Committee Member Listing Publication Positive Patient Retention High Fda Aligned Fast Track Granted

Ipo Net Proceeds Disclosure Ipo Or Capital Raising Completion Liquidity Position Snapshot Disclosed Interim Data Positive Fda Aligned Publication Positive Kol Endorsement

Clinical Trial Result Indication Expansion

Ipo Net Proceeds Disclosure Liquidity Position Snapshot Disclosed Cash Flow Statement Investing Activities Nyse Listing Disclosure Financing Activities Cash Flow Disclosure Material Weakness In Internal Controls Disclosed Net Loss Reported Capital Raising Uncertainty Disclosed Covenant Compliance Affirmation Warrant Valued Black Scholes Ipo Or Capital Raising Completion Equity Plan Board Approval Conditional On Shareholder Vote

Clinical Trial Result Lead Asset Progress Indication Expansion

Amendment Modification Waiver Clause Ipo Net Proceeds Disclosure New York Jurisdiction Clause Conflicted Defense Counsel Provision Use Of Proceeds Disclosure Ipo Or Capital Raising Completion Closing Condition Opinions And Certificates Share Withholding Tax Settlement Director Officer Indemnification Provision

Nyse Listing Disclosure Fast Track Granted Fda Aligned Fast Track Designation Received Orphan Status Granted Interim Data Positive Board Committee Member Listing Fda Breakthrough Device Designation Breakthrough Therapy Granted Patient Retention High

Secondary Endpoint Mentioned Clinical Trial Result Regulatory Designation Only Indication Expansion

Orphan Drug Designation

Equity Plan Board Approval Conditional On Shareholder Vote Auditor Appointment Ratification Quorum Presence Disclosed Classified Board Director Election

Clinical Trial Result Indication Expansion Lead Asset Progress

Patient Retention High Fast Track Granted Fast Track Designation Received Fda Aligned Orphan Status Granted

Lead Asset Progress Secondary Endpoint Mentioned Clinical Trial Result Clinical Hold Combination Therapy Mentioned

Interim Data Positive Board Committee Member Listing Fast Track Granted Publication Positive Fast Track Designation Received Enrollment Ahead Of Schedule

Trial Endpoint Missed Clinical Hold Active

Liquidity Position Snapshot Disclosed Rsu Psu Vesting Schedule Disclosed Cash Flow Statement Investing Activities Financing Activities Cash Flow Disclosure Non Employee Director Compensation Disclosed Net Loss Reported Form S3 Shelf Registration Disclosure Other Income Expense Disclosure Incorporation Or Reincorporation Disclosure Covenant Compliance Affirmation Warrant Valued Black Scholes Ipo Or Capital Raising Completion

Clinical Trial Result Indication Expansion Secondary Endpoint Mentioned

Clinical Trial Result Secondary Endpoint Mentioned Patient Enrollment Velocity

Personnel Cost Decrease Disclosure Enrollment Ahead Of Schedule

Nyse Listing Disclosure Ip Protection Methods Disclosed Board Committee Member Listing Patient Retention High Protocol Amended Enrollment Ahead Of Schedule Fda Aligned

Clinical Trial Result Combination Therapy Mentioned Secondary Endpoint Mentioned Indication Expansion